Comments for: Experimental breast cancer drug delays tumor progression 18 months

Posted Dec. 06, 2012, at 5:45 p.m.

An experimental drug showed impressive effectiveness and safety in a midstage trial against a common form of advanced breast cancer, lifting Pfizer Inc shares nearly 2 percent. The drug, called PD-0332991, delayed by more than 18 months the worsening of symptoms for postmenopausal women with the most common form of …

Guidelines for posting on bangordailynews.com

The Bangor Daily News encourages comments about stories, but you must follow our terms of service.

  1. Keep it civil and stay on topic
  2. No vulgarity, racial slurs, name-calling or personal attacks.
  3. People who harass others or joke about tragedies will be blocked.
The primary rule here is pretty simple: Treat others with the same respect you'd want for yourself. Here are some guidelines (see more):

Similar Articles

ADVERTISEMENT | Grow your business
ADVERTISEMENT | Grow your business